- Research Grants
I am a bachelor in Biological Sciences, University of Mogi das Cruzes (2002). Specialist in Protozoology in Public Health, Hospital das Clínicas, Faculty of Medicine, University of São Paulo (2004). Master (2005) and PhD (2010) in Biological Applications of Nuclear Technology, IPEN/USP. Doctorate Sandwich at the University of Zurich, Switzerland (2009). Postdoctoral by the Coordinator of Disease Control of the State Department of Health/SP. Between 2009 and 2012, I was an Assistant Researcher at the Adolfo Lutz Institute. Currently, I am a Research Scientist V at the Adolfo Lutz Institute. I am the vice-director of the Department for Systemic Parasitoses at IAL. I work with drug development for the treatment of neglected parasitic diseases. I have experience in human parasitic protozoology, molecular biology and pharmacology, with emphasis on drug delivery system and pharmacokinetic. I work mainly on the following topics: preclinical evaluation of natural and synthetic compounds and traditional drugs against protozoa causing Leishmaniasis and Chagas disease. I work with in vitro assays for drug screening, determination of its efficacy, cytotoxicity and mechanism of action; In vivo assays to determine the effective dose, route of administration and pharmacokinetic profile; Use of the drug delivery system to improve drug efficacy, and molecular biology (gene expression, qPCR and sequencing) for parasite identification and quantification. At the moment, I am coordinating a CNPq project in drug discovery for visceral leishmaniasis. I have collaborative national and international projects with Unifesp and UFABC (Brazil), Universität Munster (Germany) and University of Auckland (New Zealand). (Source: Lattes Curriculum)
The Leishmaniases are a complex of antropozoonotic infectious diseases caused by protozoan parasites Leishmania and transmitted by sandflies. Leishmaniasis is considered a major public health problem and represents a group of diseases with significant clinical and epidemiological diversity spectrum. Therapeutic regimen is restricted, due to toxicity, poor efficacy, resistance, cost and ...
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
|Data from Web of Science|